Skip to main content

TCR alpha beta / CD19+ depleted haploidentical hematopoietic

Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

  • RegistryNCT06158828
  • PhasePhase 1/2
  • StatusRecruiting
  • ConditionAcute Myeloid Leukemia, Pediatric
  • SponsorWashington University School of Medicine
How ABCD-NK worksNCT061588281 min

What the film says

Read the transcript

For high-risk acute myeloid leukemia, a bone marrow transplant is often the best chance, and a parent is usually a half-matched donor. Relapse afterward is the main way it fails.

The idea: give the new immune system a head start with trained natural killer cells from the same donor.

At Washington University in St. Louis, the donor's graft is first stripped of the T cells most likely to cause graft-versus-host disease. A week after transplant, the patient receives natural killer cells from that donor that were briefly exposed to three immune signals in the lab, which gives them a memory-like state: stronger, longer-lasting killers of leukemia. Low-dose interleukin-2 follows.

ABCD-NK is a pilot safety study led by Thomas Pfeiffer. Public record; not medical advice.

Sources behind this film

  • ClinicalTrials.gov record NCT06158828

    High-risk AML; transplant; haploidentical (parent) donor; relapse main failure; TCRαβ / CD19-depleted graft; ML NK cells infused day +7, followed by IL-2 subcutaneously; Cytokine (IL-12/15/18) pre-activation → memory-like NK (+1 more lines)

The drug

What is being tested.

The HPC product obtained from a haploidentical donor will undergo ex vivo TCR alpha beta and CD19+ depletion, and will be infused fresh on Day 0. There is no maximum limit for CD34+ dose. A maximum dose of 1 x 10^5/kg recipient weight of TCRαβ cells should not be exceeded in the final HPC product.

The ML NK cells (dose: max capped at 20 x 10^6/kg recipient weight, minimum dose allowed is 0.5 x 10^6/kg recipient weight) will be infused on Day +7.

The study

How the trial runs.

This trial represents a single institution phase I/II pilot study with the primary objective of establishing the safety and feasibility of generating and infusing ML NK cells after TCRαβ haplo-HCT.

Live record on ClinicalTrials.gov →

Eligibility

Who the study is looking for.

  • Patient Inclusion Criteria - Cohort 1:
  • High risk acute myeloid leukemia (AML) in either:
  • Complete remission (CR) defined by < 5% marrow blasts by morphology in the context of hematological recovery (ANC ≥ 0.5× 10^9/L, platelet count ≥ 50 × 10^9/L).
  • Morphological leukemia free state (MLFS) defined by the absence of hematological recovery and < 5% marrow blasts by morphology
  • Patients must further meet one of the below for inclusion into the study:
  • De novo AML in CR1 with any of the following high-risk features:

Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.

For you, or someone you love

Whether or not this trial is the one, bring AI into your corner.

A complex diagnosis brings new questions every week, in a trial and out of one. Triangle keeps your whole medical file together, reads it with you in plain language, and helps you and your family decide what to ask next.

Start your 7-day free trial

Then $9 a month. Cancel anytime.

  • Every record in one place

    Requested from your hospitals and clinics through the national networks. Add scans, pathology and anything on paper.

  • Read in plain words

    Reports explained as they come in, with lab values you can follow before treatment, during a trial and after.

  • Ready for every appointment

    Ask about your own file, and walk in with questions for your oncologist or the trial team.

  • Your people, in the loop

    Share one profile with the family helping you, and with your doctors.

Members also get a deeper analysis of their records and any sequencing data, including clinical trials that may fit, reviewed by a licensed physician before they receive it.

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.

How these trials work: what Phase 1 actually is · common questions Not clinical evidence.